Subscribe

Bayer Aktiengesellschaft (BAYN.DE)

EUR49.58 -0.34 (-0.68%)
DE XETRA Healthcare Drug Manufacturers - General
Address Kaiser-Wilhelm-Allee 1 51368
Leverkusen, NW, DE
CEO William N. Anderson
Website bayer.com
IPO 1996-12-16
ISIN DE000BAY0017

Explore sections of this company profile

Also trades on Deutsche Börse · BAYN.DE (EUR) Mexican Stock Exchange · BAYNN.MX (MXN) Other OTC · BAYRY (USD) Stuttgart Stock Exchange · BAYN.SG (EUR) Swiss Exchange · BAYN.SW (EUR) Warsaw Stock Exchange · BAY.WA (PLN)
Description

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
EUR49.58 -0.34 (-0.68%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
0.85
Float Shares
982.42M
Free Float %
100.0%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-1.22% +1.52% -6.91% -17.44% +26.82% +0.05% +53.48% -28.76% -33.48% -59.87% +183.36%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (3 ratings, all time) Hold
Price Targets & DCF
Current price
49.58
DCF (Unlevered) 115.21 +132.4%
DCF (Levered) 28.80 -41.9%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 74% Bullish
Rating 2026-05 Change
Strong Buy 7 0
Buy 7 0
Hold 5 -1
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
0.94
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - General: +6.6%
    -2.2% Q1'26: -2.4% (vs Q1'25)
  • ✗
    EPS growth Drug Manufacturers - General: +18.2%
    -41.5% Q1'26: +112.9% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - General: +36.0%
    +27.4% ★ Q1'26: -17.3% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - General: +19.4%
    +15.3% Q1'26: +23.2% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - General: +10.2%
    +12.5% ★ Q1'26: +18.6% (vs Q1'25)
  • ✓
    Share dilution Drug Manufacturers - General: +0.0%
    +0.0% Q1'26: +0.0% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×
    3.40× Q1'26: 2.23× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.84) × ERP
WACC = 51% × Ke + 49% × Kd (4.6%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 114.13 Current price: 49.58
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2011
actual 		Dec 2012
actual 		Dec 2013
actual 		Dec 2014
actual 		Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
17 Rev. Ana.
14 EPS Ana. 		Dec 2027
18 Rev. Ana.
15 EPS Ana. 		Dec 2028
13 Rev. Ana.
10 EPS Ana. 		Dec 2029
12 Rev. Ana.
4 EPS Ana. 		Dec 2030
6 Rev. Ana.
4 EPS Ana.
Revenue
36.53B
est: 36.97B (-1.2%)
39.74B
est: 40.14B (-1.0%)
40.16B
est: 41.03B (-2.1%)
41.34B
est: 42.47B (-2.7%)
46.09B
est: 46.29B (-0.5%)
34.94B
est: 46.74B (-25.2%)
35.02B
est: 35.33B (-0.9%)
36.74B
est: 39.27B (-6.4%)
43.55B
est: 43.92B (-0.8%)
41.40B
est: 41.51B (-0.3%)
44.08B
est: 43.38B (+1.6%)
50.74B
est: 50.68B (+0.1%)
47.64B
est: 47.11B (+1.1%)
46.61B
est: 46.39B (+0.5%)
45.58B
est: 45.59B (0.0%)
45.45B
44.39B – 46.32B
-0.3% YoY
46.55B
45.72B – 48.93B
+2.4% YoY
48.34B
48.25B – 48.43B
+3.8% YoY
49.85B
48.83B – 51.61B
+3.1% YoY
49.94B
48.91B – 51.70B
+0.2% YoY
EBITDA
7.11B
est: 4.90B (+44.9%)
7.93B
est: 6.21B (+27.6%)
7.35B
est: 5.92B (+24.1%)
8.20B
est: 6.92B (+18.4%)
9.38B
est: 7.57B (+24.0%)
8.05B
est: 7.77B (+3.6%)
8.03B
est: 6.27B (+28.0%)
4.28B
est: 11.10B (-61.4%)
9.65B
est: 6.92B (+39.4%)
4.30B
est: 8.39B (-48.8%)
11.67B
est: 8.70B (+34.2%)
12.19B
est: 8.83B (+38.0%)
12.34B
est: 11.20B (+10.2%)
8.53B
est: 11.09B (-23.1%)
11.01B
est: 10.84B (+1.6%)
10.80B
10.55B – 11.01B
-0.3% YoY
11.07B
10.87B – 11.63B
+2.4% YoY
11.49B
11.47B – 11.51B
+3.8% YoY
11.85B
11.61B – 12.27B
+3.1% YoY
11.87B
11.63B – 12.29B
+0.2% YoY
EBIT
4.58B
est: 2.88B (+59.0%)
5.29B
est: 4.53B (+16.8%)
4.74B
est: 4.05B (+17.0%)
5.50B
est: 5.10B (+7.8%)
6.28B
est: 5.99B (+4.8%)
5.70B
est: 6.37B (-10.5%)
5.89B
est: 4.33B (+36.0%)
1.39B
est: 6.63B (-79.1%)
5.21B
est: 3.83B (+36.2%)
12.00M
est: 4.14B (-99.7%)
7.93B
est: 4.29B (+85.0%)
8.24B
est: 4.35B (+89.3%)
8.41B
est: 7.23B (+16.3%)
4.48B
est: 7.16B (-37.4%)
6.95B
est: 7.00B (-0.6%)
6.98B
6.81B – 7.11B
-0.3% YoY
7.14B
7.02B – 7.51B
+2.4% YoY
7.42B
7.41B – 7.43B
+3.8% YoY
7.65B
7.49B – 7.92B
+3.1% YoY
7.67B
7.51B – 7.94B
+0.2% YoY
Net Income
2.47B
est: 1.37B (+79.8%)
2.40B
est: 2.69B (-10.8%)
3.19B
est: 2.50B (+27.5%)
3.43B
est: 3.30B (+3.8%)
4.11B
est: 3.80B (+8.0%)
4.53B
est: 4.20B (+7.9%)
7.34B
est: 3.42B (+114.6%)
1.70B
est: 8.23B (-79.4%)
4.09B
est: 1.88B (+117.9%)
-10.50B
est: 4.04B (-359.8%)
1.00B
est: 4.19B (-76.1%)
4.15B
est: 1.45B (+186.6%)
-2.94B
est: -1.27B (-132.3%)
-2.55B
est: 4.94B (-151.7%)
-3.62B
est: 4.67B (-177.6%)
4.20B
3.85B – 4.55B
-10.0% YoY
4.65B
4.04B – 5.26B
+10.7% YoY
5.61B
4.27B – 6.94B
+20.6% YoY
5.48B
5.33B – 5.73B
-2.4% YoY
4.57B
4.45B – 4.78B
-16.6% YoY
SGA
10.69B
est: 11.86B (-9.9%)
11.52B
est: 11.99B (-3.9%)
11.94B
est: 13.55B (-11.9%)
12.44B
est: 12.46B (-0.2%)
14.52B
est: 12.61B (+15.1%)
13.10B
est: 13.40B (-2.2%)
13.26B
est: 9.88B (+34.1%)
14.88B
est: 14.88B (0.0%)
15.43B
est: 16.49B (-6.4%)
15.14B
est: 16.02B (-5.5%)
14.03B
est: 16.61B (-15.5%)
16.22B
est: 16.86B (-3.8%)
14.33B
est: 14.76B (-2.9%)
14.68B
est: 14.62B (+0.4%)
14.27B
est: 14.29B (-0.1%)
14.24B
13.91B – 14.52B
-0.3% YoY
14.59B
14.33B – 15.33B
+2.4% YoY
15.15B
15.12B – 15.18B
+3.8% YoY
15.62B
15.30B – 16.17B
+3.1% YoY
15.65B
15.33B – 16.20B
+0.2% YoY
EPS
2.94
est: 4.77 (-38.4%)
2.86
est: 5.46 (-47.6%)
3.80
est: 5.75 (-33.9%)
4.07
est: 6.04 (-32.6%)
4.89
est: 6.87 (-28.8%)
5.35
est: 7.27 (-26.4%)
8.28
est: 6.56 (+26.3%)
1.80
est: 5.82 (-69.1%)
4.17
est: 6.39 (-34.8%)
-10.68
est: 6.31 (-269.3%)
1.02
est: 6.23 (-83.6%)
4.22
est: 7.78 (-45.8%)
-2.99
est: -1.29 (-132.0%)
-2.60
est: 4.98 (-152.3%)
-3.68
est: 4.70 (-178.4%)
4.29
3.92 – 4.63
-8.6% YoY
4.67
4.11 – 5.35
+8.9% YoY
5.26
4.35 – 7.07
+12.5% YoY
5.57
5.43 – 5.83
+6.0% YoY
4.65
4.53 – 4.86
-16.6% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-12 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-05-11 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-05-08 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-05-07 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-05-06 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-05-05 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-05-04 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-04-30 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-04-29 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-04-28 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-04-27 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-04-24 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-04-23 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-04-22 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-04-21 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-04-20 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-04-17 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-04-16 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5
2026-04-15 C+ 2/5 4/5 1/5 1/5 1/5 1/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
2.64B
OE per share TTM
2.68
Owner's Yield
6.82%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
28.2%

Ownership Overview

Ownership breakdown
At a glance
Institutional holders
1
Total invested
765.3K
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend From To
13F snapshot — 2026 Q1
Investors holding
1
+1 vs prev Q
New positions
1
Closed positions
0
Increased
1
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
# Investor ⇅ Shares / Δ ⇅ Mkt value / Δ ⇅ Own% / Δ ⇅ Weight% / Δ ⇅ Avg px / Perf. ⇅ Hold / Status ⇅
1 GENERALI INVESTMENTS CEE, INVESTICNI SPOLECNOST, A.S. 16.7K +16.7K (+100.0%) 765.3K +765.3K (+100.0%) 0.00% +0.002 pp 0.04% +0.040 pp EUR39.39 +0.0% 1 qtrs NEW
Ownership breakdown by holder

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
75.8K
Shares Outstanding
982.42M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
William N. Anderson Chairman of the Management Board & Chief Executive Officer 6M male
Heike Prinz Chief Talent Officer, Labor Director & Member of Management Board 2M female
Rodrigo Santos Member of Management Board, Head of the Crop Science Division & President of Crop Science Division 2M male
Wolfgang U. Nickl Chief Financial Officer & Member of Management Board 2M male
Stefan Oelrich Head of the Pharmaceuticals Division & Member of the Board of Management 2M male
Julio Triana Member of Management Board & President of Consumer Health Division 2M male
Michael Preuss Head of Communications, Government Relations and Corporate Brand — male
Alex Buschermohle Chief Information Officer, Head-Digital Transformation & IT-Crop Science Division — male
Judith Hartmann Member of Management Board — —
Jost Reinhard Senior Vice President & Head of Investor Relations — —
Bill Dodero General Counsel and Senior Vice President of Law Patents & Compliance — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - General